Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK.

Alfonso Gomez de Liano,Balaji Venugopal,Kate Fife,Luma Khasti,Stefan Symeonides,Claire Pettinger,Thomas Powles,Sarah Rudman,Naveen S. Vasudev,Ekaterini Boleti

Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK.

2018

Alfonso Gomez de Liano
Balaji Venugopal
Kate Fife
Luma Khasti
Stefan Symeonides
Claire Pettinger
Thomas Powles
Sarah Rudman
Naveen S. Vasudev
Ekaterini Boleti

e16578Background: The randomised phase III METEOR trial showed survival benefit of cabozantinib over everolimus in patients with mRCC who progressed after VEGF targeted therapy. We report real worl...

Keywords:

Pathology
Renal cell carcinoma
Cabozantinib
Medicine
Cancer research
survival benefit
Everolimus
in patient
Oncology
VEGF receptors
Internal medicine
Targeted therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations